

Anthony J Lembo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4540029/anthony-j-lembo-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

156 papers	11,227 citations	51 h-index	105 g-index
174 ext. papers	13,561 ext. citations	6.1 avg, IF	6.29 L-index

#	Paper	IF	Citations
156	Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D.. <i>Gut Microbes</i> , 2022 , 14, 2020067	8.8	5
155	Genotypes of Pain and Analgesia in a Randomized Trial of Irritable Bowel Syndrome.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 842030	5	1
154	Training in GI Upper Motility Techniques 2022 , 395-409		
153	Genomic Effects Associated With Response to Placebo Treatment in a Randomized Trial of Irritable Bowel Syndrome.. <i>Frontiers in Pain Research</i> , 2021 , 2, 775386	1.4	2
152	Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2). <i>American Journal of Gastroenterology</i> , 2021 , 116, 1294-1303	0.7	6
151	Diminished androgen levels are linked to irritable bowel syndrome and cause bowel dysfunction in mice. <i>Journal of Clinical Investigation</i> , 2021 ,	15.9	2
150	Management of irritable bowel syndrome with diarrhea: focus on eluxadoline. <i>Current Medical Research and Opinion</i> , 2021 , 37, 567-578	2.5	1
149	Abdominal Pain and Depression, Not Bowel Habits, Predict Health Care Utilization in Patients With Functional Bowel Disorders. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1720-1726	0.7	1
148	Improving Medication Tolerance: A Pilot Study in Disorders of Gut-brain Interaction Treated With Tricyclic Antidepressants. <i>Journal of Clinical Gastroenterology</i> , 2021 ,	3	3
147	Clinical and Psychological Factors Predict Outcome in Patients With Functional Dyspepsia: A Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
146	Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 4140-4148	4	2
145	Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial. <i>Pain</i> , 2021 , 162, 2428-2435	8	16
144	Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2021 , 116, 2279-2285	0.7	5
143	Symptom severity and clinical characteristics of patients with bloating. <i>Neurogastroenterology and Motility</i> , 2021 , e14229	4	1
142	Evaluating the Impact of Cost on the Treatment Algorithm for Chronic Idiopathic Constipation: Cost-Effectiveness Analysis. <i>American Journal of Gastroenterology</i> , 2021 , 116, 2118-2127	0.7	1
141	Efficacy of Prucalopride for Chronic Idiopathic Constipation: An Analysis of Participants With Moderate to Very Severe Abdominal Bloating. <i>American Journal of Gastroenterology</i> , 2021 ,	0.7	2
140	Improvement in constipation and diarrhea is associated with improved abdominal pain in patients with functional bowel disorders. <i>Neurogastroenterology and Motility</i> , 2021 , e14253	4	1

139	Emerging Role of the Gut Microbiome in Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2021 , 50, 523-545	4.4	2
138	Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M).. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54 Suppl 1, S63-S74	6.1	0
137	Fecal Urgency: Clinical and Manometric Characteristics in Patients With and Without Diarrhea. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3679-3687	4	2
136	Effects of the vibrating capsule on colonic circadian rhythm and bowel symptoms in chronic idiopathic constipation. <i>Neurogastroenterology and Motility</i> , 2020 , 32, e13890	4	10
135	Brief Behavioral Therapy for Insomnia in Patients with Irritable Bowel Syndrome: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3260-3270	4	4
134	Symptom Severity, Mood, and Healthcare Use Are Associated With Satisfaction in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2945-2951.e1	6.9	4
133	Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1). <i>American Journal of Gastroenterology</i> , 2020 , 115, 281-293	0.7	33
132	Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D: Additional post hoc analyses of Phase 3 trials. <i>Neurogastroenterology and Motility</i> , 2020 , 32, e13774	4	5
131	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. <i>CNS Drugs</i> , 2020 , 34, 185-196	6.7	32
130	Microbiome and Its Role in Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 829-839	4	42
129	Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00144	4.2	3
128	Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1139-1148	6.1	8
127	Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey. <i>Gastroenterology</i> , 2020 , 158, 786-788.e1	13.3	16
126	Information- and Health-care Seeking Behaviors in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2840-2842	6.9	2
125	Similarities in Clinical and Psychosocial Characteristics of Functional Diarrhea and Irritable Bowel Syndrome With Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 399-405.e1	6.9	8
124	Difference in Defecation Desire Between Patients With and Without Chronic Constipation: A Large-Scale Internet Survey. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00230	4.2	2
123	The international anorectal physiology working group (IAPWG) recommendations: Standardized testing protocol and the London classification for disorders of anorectal function. <i>Neurogastroenterology and Motility</i> , 2020 , 32, e13679	4	70
122	Obesity is associated with significantly increased risk for diarrhoea after controlling for demographic, dietary and medical factors: a cross-sectional analysis of the 2009-2010 National Health and Nutrition Examination Survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1019-1024	6.1	12

121	Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D. <i>United European Gastroenterology Journal</i> , 2019 , 7, 709-715	5.3	25
120	Pelvic Floor Symptom Related Distress in Chronic Constipation Correlates With a Diagnosis of Irritable Bowel Syndrome With Constipation and Constipation Severity but Not Pelvic Floor Dyssynergia. <i>Journal of Neurogastroenterology and Motility</i> , 2019 , 25, 129-136	4.4	5
119	Chronic Diarrhea and Constipation Are More Common in Depressed Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2696-2703	6.9	18
118	Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 397-406	4.2	10
117	Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819841290	4.7	9
116	Effects of Irritable Bowel Syndrome on Daily Activities Vary Among Subtypes Based on Results From the IBS in America Survey. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2471-2478.e3	6.9	24
115	Fecal urgency is common in constipated patients and is associated with anxiety. <i>Neurogastroenterology and Motility</i> , 2019 , 31, e13545	4	7
114	Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome. <i>Clinical and Translational Gastroenterology</i> , 2019 , 10, e00110	4.2	7
113	Safety of Endoscopy in Heritable Connective Tissue Disorders. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1343-1345	0.7	3
112	Prevalence of Chronic Constipation and Chronic Diarrhea in Diabetic Individuals in the United States. <i>American Journal of Gastroenterology</i> , 2019 , 114, 135-142	0.7	31
111	Significant Morbidity and Mortality Associated with Fecal Impaction in Patients Who Present to the Emergency Department. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 1320-1327	4	6
110	The Prevalence of Gastroesophageal Reflux in Patients With Excessive Central Airway Collapse. <i>Chest</i> , 2019 , 155, 540-545	5.3	7
109	Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. <i>Gut Microbes</i> , 2019 , 10, 22-33	8.8	39
108	Demographic and Dietary Associations of Chronic Diarrhea in a Representative Sample of Adults in the United States. <i>American Journal of Gastroenterology</i> , 2018 , 113, 593-600	0.7	25
107	Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 913-921	6.1	22
106	Risk Factors for Fecal Urgency Among Individuals With and Without Diarrhea, Based on Data From the National Health and Nutrition Examination Survey. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1450-1458.e2	6.9	7
105	Factors Associated With Response to Placebo in Patients With Irritable Bowel Syndrome and Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1738-1744.e1	6.9	21
104	Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1569-1584.e2	6.9	51

103	Low-Dose Linaclotide (72 g) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2018 , 113, 105-114	0.7	33
102	Reduction in pain: Is it worth the gain? The effect of opioids on the GI tract. <i>Neurogastroenterology and Motility</i> , 2018 , 30, e13367	4	8
101	Sleep Disturbances Are Commonly Reported Among Patients Presenting to a Gastroenterology Clinic. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 2983-2991	4	23
100	Clinical and manometric characteristics of women with paradoxical puborectalis syndrome. <i>United European Gastroenterology Journal</i> , 2018 , 6, 1578-1585	5.3	1
99	A169 EFFICACY AND SAFETY OF ELUXADOLINE IN ELDERLY PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018 , 1, 252-253	0.5	1
98	Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial. <i>American Journal of Gastroenterology</i> , 2017 , 112, 763-774	0.7	60
97	Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. <i>American Journal of Gastroenterology</i> , 2017 , 112, 924-932	0.7	29
96	Reply. <i>Gastroenterology</i> , 2017 , 152, 1630-1631	13.3	
95	Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 1480-1485	4	20
94	Gender differences in chronic constipation on anorectal motility. <i>Neurogastroenterology and Motility</i> , 2017 , 29, e12980	4	12
93	Pseudoachalasia Secondary to Thoracic Aortic Aneurysm. <i>Annals of Thoracic Surgery</i> , 2017 , 103, e517-e518	18	6
92	Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1338-1349	6.9	73
91	Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 2455-2463	4	29
90	Emergency Department Burden of Diverticulitis in the USA, 2006-2013. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 2694-2703	4	30
89	Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. <i>American Journal of Gastroenterology</i> , 2017 , 112, 775-784	0.7	343
88	Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. <i>Therapeutic Advances in Gastroenterology</i> , 2017 , 10, 689-699	4.7	8
87	Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population. <i>Therapeutic Advances in Gastroenterology</i> , 2017 , 10, 673-687	4.7	2
86	Chronic constipation. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17095	51.1	106

85	Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial. <i>Trials</i> , 2017 , 18, 234	2.8	31
84	Irritable bowel syndrome and diet. <i>Gastroenterology Report</i> , 2017 , 5, 11-19	3.3	29
83	Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2016 , 151, 1113-1121	13.3	147
82	OC-070 Eluxadoline Demonstrates Efficacy for the Treatment of Irritable Bowel Syndrome (IBS) with Diarrhoea (IBS-D) Among Multiple Clinically Relevant Patient Subgroups. <i>Gut</i> , 2016 , 65, A42-A43	19.2	1
81	Eluxadoline for Irritable Bowel Syndrome with Diarrhea. <i>New England Journal of Medicine</i> , 2016 , 374, 242-53	59.2	185
80	Fecal Impaction in the Emergency Department: An Analysis of Frequency and Associated Charges in 2011. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, 572-7	3	15
79	Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2016 ,	13.3	20
78	Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. <i>Gastroenterology</i> , 2016 ,	13.3	242
77	Bowel Disorders. <i>Gastroenterology</i> , 2016 ,	13.3	1260
76	Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis. <i>Gastroenterology</i> , 2016 , 151, 87-96.e6	13.3	85
75	Complementary and Alternative Medicine Use Is Prevalent Among Patients with Gastrointestinal Diseases. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 1883-8	4	94
74	Response to Pasalar et al. <i>American Journal of Gastroenterology</i> , 2015 , 110, 936	0.7	
73	Emergency department burden of constipation in the United States from 2006 to 2011. <i>American Journal of Gastroenterology</i> , 2015 , 110, 572-9	0.7	67
72	Novel Therapies in IBS-D Treatment. <i>Current Treatment Options in Gastroenterology</i> , 2015 , 13, 432-40	2.5	7
71	Inpatient burden of childhood functional GI disorders in the USA: an analysis of national trends in the USA from 1997 to 2009. <i>Neurogastroenterology and Motility</i> , 2015 , 27, 684-92	4	60
70	Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2781-92	4	6
69	Complementary and Alternative Management Strategies in Irritable Bowel Syndrome 2015 , 253-259		1
68	Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C. <i>United European Gastroenterology Journal</i> , 2015 , 3, 53-62	5.3	9

67	Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation. <i>Pain Medicine</i> , 2015 , 16, 2324-37	2.8	81
66	Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. <i>PLoS ONE</i> , 2015 , 10, e0126438	3.7	83
65	Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial. <i>PLoS ONE</i> , 2015 , 10, e0134349	3.7	50
64	Patient-Provider Interactions Affect Symptoms in Gastroesophageal Reflux Disease: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial. <i>PLoS ONE</i> , 2015 , 10, e0136855	3.7	20
63	Complementary and alternative medicine use by US adults with gastrointestinal conditions: Results from the 2012 National Health Interview Survey. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1705-17	3.7	59
62	Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2014 , 2, 31-7		77
61	American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. <i>Gastroenterology</i> , 2014 , 147, 1149-72.e2	13.3	90
60	Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1547-61; quiz 1546, 1562	0.7	447
59	American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. <i>American Journal of Gastroenterology</i> , 2014 , 109, Suppl 1, S2-26; quiz S27	0.7	393
58	Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1350-65; quiz 1366	0.7	262
57	Qualitative development of a patient-reported outcome symptom measure in diarrhea-predominant irritable bowel syndrome. <i>Clinical and Translational Gastroenterology</i> , 2014 , 5, e59	4.2	8
56	Introduction: opioid-induced constipation. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2014 , 2, 2		1
55	Irritable bowel syndrome subtypes: constipation, diarrhea and mixed bowel pattern: tertium datur. <i>Neurogastroenterology and Motility</i> , 2014 , 26, 1-2	4	1
54	Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1161-8	6.1	67
53	Opioid-induced bowel dysfunction. <i>Current Gastroenterology Reports</i> , 2013 , 15, 344	5	49
52	In-patient discharge rates for the irritable bowel syndrome - an analysis of national trends in the United States from 1997 to 2010. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 1338-46	6.1	14
51	Diagnostic testing for dyssynergic defecation in chronic constipation: meta-analysis. <i>Neurogastroenterology and Motility</i> , 2013 , 25, 509-20	4	59
50	Phase 2b, randomized, double-blind 12-week studies of TZIP-102, a ghrelin receptor agonist for diabetic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2013 , 25, e705-17	4	78

49	PWE-027 Mediation Analysis Supports a Direct Effect of Linaclotide (LIN) on Abdominal Pain (AP) Relief Independent of Constipation Improvement. <i>Gut</i> , 2013 , 62, A141.1-A141	19.2	
48	Successful Treatment with Methylnaltrexone and IVIG for Paraneoplastic Syndrome-Associated Intestinal Pseudo-Obstruction. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 48-51	0.7	2
47	Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. <i>American Journal of Medicine</i> , 2012 , 125, 381-93	2.4	56
46	Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1702-12	0.7	292
45	A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1714-24; quiz p.1725	0.7	260
44	Severity in irritable bowel syndrome: a Rome Foundation Working Team report. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1749-59; quiz 1760	0.7	145
43	Rifaximin therapy for patients with irritable bowel syndrome without constipation. <i>New England Journal of Medicine</i> , 2011 , 364, 22-32	59.2	690
42	Evolving concepts in chronic constipation in Europe and elsewhere: not worlds apart. <i>Neurogastroenterology and Motility</i> , 2011 , 23, 693-6	4	5
41	Long-term safety and effectiveness of lubiprostone, a chloride channel (CLC-2) activator, in patients with chronic idiopathic constipation. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 2639-45	4	75
40	Complementary and alternative medicine for the irritable bowel syndrome. <i>Gastroenterology Clinics of North America</i> , 2011 , 40, 245-53	4.4	23
39	Two randomized trials of linaclotide for chronic constipation. <i>New England Journal of Medicine</i> , 2011 , 365, 527-36	59.2	248
38	Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 1192-202	6.1	25
37	Efficacy of linaclotide for patients with chronic constipation. <i>Gastroenterology</i> , 2010 , 138, 886-95.e1	13.3	184
36	Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. <i>Gastroenterology</i> , 2010 , 139, 1877-1886.e2	13.3	173
35	Which patients improve: characteristics increasing sensitivity to a supportive patient-practitioner relationship. <i>Social Science and Medicine</i> , 2010 , 70, 479-484	5.1	33
34	Placebos without deception: a randomized controlled trial in irritable bowel syndrome. <i>PLoS ONE</i> , 2010 , 5, e15591	3.7	497
33	Psychiatric disorder, irritable bowel syndrome, and extra-intestinal symptoms in a population-based sample of twins. <i>American Journal of Gastroenterology</i> , 2009 , 104, 686-94	0.7	18
32	Adequate relief in a treatment trial with IBS patients: a prospective assessment. <i>American Journal of Gastroenterology</i> , 2009 , 104, 912-9	0.7	32

31	A treatment trial of acupuncture in IBS patients. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1489-97	9.7	90
30	Treatment of Helicobacter pylori infection with intra-gastric violet light phototherapy: a pilot clinical trial. <i>Lasers in Surgery and Medicine</i> , 2009 , 41, 337-44	3.6	53
29	"Maybe I made up the whole thing": placebos and patients' experiences in a randomized controlled trial. <i>Culture, Medicine and Psychiatry</i> , 2009 , 33, 382-411	2.5	101
28	Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 1159-70	6.1	73
27	Delayed radionuclide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. <i>Gastroenterology</i> , 2009 , 137, 445-52	13.3	106
26	Pilot study on the effect of linaclotide in patients with chronic constipation. <i>American Journal of Gastroenterology</i> , 2009 , 104, 125-32	0.7	100
25	Psychiatric Disorder, Irritable Bowel Syndrome, and Extra-Intestinal Symptoms in a Population-Based Sample of Twins. <i>American Journal of Gastroenterology</i> , 2009 , 104, 686-694	0.7	
24	Effectiveness of recruitment in clinical trials: an analysis of methods used in a trial for irritable bowel syndrome patients. <i>Contemporary Clinical Trials</i> , 2008 , 29, 241-51	2.3	30
23	Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. <i>BMJ, The</i> , 2008 , 336, 999-1003	5.9	818
22	Opioid-induced bowel dysfunction. <i>Current Treatment Options in Gastroenterology</i> , 2008 , 11, 11-8	2.5	6
21	Endoscopic full-thickness plication for the treatment of GERD: Five-year long-term multicenter results. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2008 , 22, 326-32	5.2	44
20	Highlights from the 2007 ACG. <i>Gastroenterology and Hepatology</i> , 2008 , 4, 118-22	0.7	
19	Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 1343-50	6.1	118
18	Endoscopic full-thickness plication for the treatment of GERD: long-term multicenter results. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2007 , 21, 439-44	5.2	55
17	Current gut-directed therapies for irritable bowel syndrome. <i>Current Treatment Options in Gastroenterology</i> , 2006 , 9, 314-23	2.5	16
16	Peripheral opioids for functional GI disease: a reappraisal. <i>Digestive Diseases</i> , 2006 , 24, 91-8	3.2	10
15	A 54-year-old woman with constipation-predominant irritable bowel syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 925-33	27.4	2
14	Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease: A randomized, sham-controlled trial. <i>Gastroenterology</i> , 2006 , 131, 704-12	13.3	123

13	Investigating placebo effects in irritable bowel syndrome: a novel research design. <i>Contemporary Clinical Trials</i> , 2006 , 27, 123-34	2.3	23
12	Endoscopic full-thickness plication for the treatment of GERD: 12-month follow-up for the North American open-label trial. <i>Gastrointestinal Endoscopy</i> , 2005 , 61, 643-9	5.2	80
11	Irritable bowel syndrome: toward an understanding of severity. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 717-25	6.9	78
10	Review of tegaserod in the treatment of irritable bowel syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 2369-79	4	13
9	Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. <i>Clinical Gastroenterology and Hepatology</i> , 2004 , 2, 675-82	6.9	51
8	Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. <i>Clinical Gastroenterology and Hepatology</i> , 2004 , 2, 796-805	6.9	144
7	Endoscopic full-thickness plication for the treatment of GERD: a multicenter trial. <i>Gastrointestinal Endoscopy</i> , 2004 , 59, 163-71	5.2	108
6	Irritable bowel syndrome medications side effects survey. <i>Journal of Clinical Gastroenterology</i> , 2004 , 38, 776-81	3	22
5	Chronic constipation. <i>New England Journal of Medicine</i> , 2003 , 349, 1360-8	59.2	580
4	Irritable bowel syndrome: evaluation and treatment. <i>Gastroenterology Clinics of North America</i> , 2003 , 32, 507-29	4.4	10
3	Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder. <i>Drugs</i> , 2003 , 63, 1895-905	12.1	16
2	A novel endoscopic full-thickness plicator for the treatment of GERD: A pilot study. <i>Gastrointestinal Endoscopy</i> , 2003 , 58, 770-6	5.2	74
1	Complementary and Alternative Medicine in Gastroenterology 2521-2532		1